Document:

EX-10.13

 EXHIBIT 10.13 

MERIDIAN BIOSCIENCE, INC. 

2012 STOCK INCENTIVE PLAN 

NONQUALIFIED STOCK OPTION AGREEMENT 

PERFORMANCE AWARD 
 Summary of
Nonqualified Stock Option Grant 
 Meridian Bioscience, Inc., an Ohio corporation (the “Company”), grants to the Grantee
named below, in accordance with the terms of the Meridian Bioscience, Inc. 2012 Stock Incentive Plan, a copy of which is available on the Bank of America Merrill Lynch website at www.benefits.ml.com (the “Plan”) and this
Nonqualified Stock Option Agreement (the “Agreement”), an option to purchase Shares of the Common Stock of the Company at an exercise price per Share as described below: 

 

					
	 Name of Grantee:
	 	                                   
                                         
     
		
	 Number of Underlying Shares:
	 	                                   
       
		
	 Exercise Price Per Share:
	 	  **                                 
   
			
	 Grant Date:
	 	 November 8, 2017	 	
			
	 Vesting Date(s):
	 	25%	 	 November 15, 2018

		 	25%	 	 November 15, 2019

		 	25%	 	 November 15, 2020

		 	25%	 	 November 15, 2021

			
	 Expiration Date:
	 	 November 8, 2027	 	

 Terms of Agreement 

1.    Grant of Nonqualified Stock Option. Subject to and upon the terms, conditions, and restrictions set
forth in this Agreement and in the Plan, the Company hereby grants to the Grantee as of the Grant Date, an option to purchase Shares of Common Stock of the Company at an exercise price per Share as set forth above (the “Option”). It
is the intent of the Company and the Grantee that the Option will not qualify as an “incentive stock option” under Section 422 of the Internal Revenue Code of 1986, as amended from time to time. 

2.    Vesting of Option. 

(a)    Except as otherwise provided in this Agreement, the Option shall not vest and shall become void and be of no further
effect at the time net earnings for Meridian’s fiscal year ended September 30, 2018 are determined and such earnings are released to the public unless such net earnings (the “Actual Earnings”) exceed $********, subject to
treatment of certain items as defined in Section V of the 2018 Cash-Based Incentive Compensation Plan (Corporate Incentive Compensation Plan) (the “Earnings Target”). If the Actual Earnings exceed the Earnings Target, this Option
shall continue in full force and effect in accordance with the terms and conditions of the Plan and this Agreement and such Option shall vest 25% per year on the respective Vesting Dates identified above. 

(b)    The Option shall vest in full prior to the Vesting Date(s) upon the occurrence of any of the following:
(i) the Grantee dies while in the employ of the Company; (ii) the Grantee satisfies the 

 
requirements for Retirement, as defined in the Plan, including separation from employment with the Company; (iii) the Grantee has a Disability, as defined in the Plan; or (iv) there is
a Change in Control event described in Section 2(g) of the Plan. The Option shall be exercisable for ninety days following the occurrence of the condition described in Section 2(b)(ii). The Option shall be exercisable for one year
following the occurrence of the conditions described in Sections 2(b)(i) and 2(b)(iii). 
 (c)    In no event shall any
portion of the Option vest if Grantee’s Retirement occurs prior to March 31, 2018. For the avoidance of doubt, if Grantee’s Retirement occurs prior to March 31, 2018, Grantee shall forfeit the Option even if the Actual Earnings
exceed the Earnings Target. 
 (d)    If Grantee’s Retirement occurs after March 31, 2018 but before any
determination and release to the public of earnings as described in Section 2(a), the Option shall vest upon, and only upon, the later determination and release to the public that the Actual Earnings exceed the Earnings Target. 

(e)    In the event that after the determination and release to the public as described in Section 2(a) the Actual
Earnings exceed the Earnings Target Grantee’s employment with the Company is terminated due to the Grantee’s death, Disability, or Retirement including separation from employment, all of the Option shall vest in full upon Grantee’s
death, Disability or Retirement, as the case may be. 
 (f)    The Committee may, in its sole discretion, accelerate the
time at which the Option becomes vested and non-forfeitable to a time other than the Vesting Date(s) as provided in Section 2(a) or to a time other than provided in Section (2)(b)(i), (ii), (iii) or
(iv) on such terms and conditions as it deems appropriate in accordance with the terms and conditions of the Plan. 

3.    Forfeiture of Option. Any portion of the Option that has not yet vested pursuant to Section 2
shall be forfeited automatically without further action or notice if the Grantee ceases to be employed by the Company other than as provided in Section 2(b) or (c) hereof. 

4.    Exercise and Payment. 

(a)    The Option granted under this Agreement shall be exercisable on the Vesting Date(s) as provided on the first page
under “Summary of Nonqualified Stock Option Grant” herein. The Option granted under this Agreement may not be exercised as to less than twenty-five (25) Shares at any time. 

(b)    The Option may be exercised for the number of Shares specified by Grantee’s delivery of instructions through
and in accordance with the procedures established under the Merrill Lynch system maintained on behalf of the Company, accompanied by full payment in the manner and subject to the conditions set forth pursuant to the terms of the Plan for the number
of Shares in respect of which it is exercised. If any applicable law or regulation requires the Company to take any action with respect to the Shares specified in such notice, or if any action remains to be taken under the Articles of
Incorporation or Code of Regulations of the Company to effect due issuance of the Shares, then the Company shall take such action and the day for delivery of such stock shall be extended for the period necessary to take such action. 

5.    Transferability. The Option may not be transferred and shall not be subject in any manner to
assignment, alienation, pledge, encumbrance or charge, unless otherwise provided under the Plan. Any purported Transfer or encumbrance in violation of the provisions of this Section 5 shall be void, and the other party to any such purported
transaction shall not obtain any rights to or interest in the Option. 
 6.    Voting and Other Rights.
The Grantee will not have any rights of a shareholder of the Company with respect to the Option until the delivery of the underlying Shares into which the Option is exercised. 

7.    Continuous Employment. Unless otherwise specified by the Plan, for purposes of this Agreement, the
continuous employment of the Grantee with the Company shall not be deemed to have been interrupted, and the Grantee shall not be deemed to have ceased to be an employee of the Company, by reason of the transfer of his employment among the Company or
a leave of absence approved by the Committee. 

  
 - 2 - 

 8.    No Employment Contract. Nothing contained in this
Agreement shall confer upon the Grantee any right with respect to continuance of employment by the Company, nor limit or affect in any manner the right of the Company to terminate the employment or adjust the compensation of the Grantee. 

9.    Relation to Other Benefits. Any economic or other benefit to the Grantee under this Agreement or the
Plan shall not be taken into account in determining any benefits to which the Grantee may be entitled under any profit-sharing, retirement or other benefit or compensation plan maintained by the Company and shall not affect the amount of any life
insurance coverage available to any beneficiary under any life insurance plan covering employees of the Company.  

10.    Taxes and Withholding. By his or her acceptance of this Agreement, the Grantee agrees to reimburse
the Company for any taxes required by any government to be withheld or otherwise deducted and paid by the Company with respect to the issuance or disposition of the Shares subject to the Option. In lieu thereof, the Company shall have the right to
withhold the amount of such taxes from any other sums due or to become due from the Company to the Participant. The Company may, in its discretion, hold the stock certificate or certificates to which the Grantee is entitled upon the exercise of the
Option as security for the payment of such withholding tax liability, until cash sufficient to pay that liability has been accumulated. In addition, at any time that the Company becomes subject to a withholding obligation under applicable law with
respect to the exercise of the Option (the “Tax Date”), except as set forth below, a holder of the Option may elect to satisfy, in whole or in part, the holder’s related personal tax liabilities (an “Election”)
by (a) directing the Company to withhold from Shares issuable in the related exercise either a specified number of Shares or Shares having a specified value (in each case not in excess of the minimum required tax withholding amount),
(b) tendering Shares previously issued pursuant to the exercise of an Award or other Shares owned by the holder or (c) combining any or all of the foregoing Elections in any fashion. An Election shall be irrevocable. The withheld Shares
and other Shares tendered in payment shall be valued at their Fair Market Value on the Tax Date. The Committee may disapprove of any Election, suspend or terminate the right to make Elections or provide that the right to make Elections shall not
apply to particular Shares or exercises. The Committee may impose any additional conditions or restrictions on the right to make an Election as it shall deem appropriate, including any limitations necessary to comply with Section 16 of the
Exchange Act.  
 11.    Adjustments. The number and kind of Shares deliverable pursuant to the
Option are subject to adjustment as provided in Section 8 of the Plan.  

12.    Compliance with Law. While the Company shall make reasonable efforts to comply with all applicable
federal and state securities laws and listing requirements with respect to the Shares that may be delivered pursuant hereto, the Company shall not be obligated to deliver any Shares pursuant to this Agreement if the delivery thereof would result in
a violation of any such law or listing requirement. 
 13.    Amendments. Subject to the terms of the
Plan, the Committee may modify this Agreement upon written notice to the Grantee. Any amendment to the Plan shall be deemed to be an amendment to this Agreement to the extent that the amendment is applicable hereto. 

14.    Severability. In the event that one or more of the provisions of this Agreement shall be invalidated
for any reason by a court of competent jurisdiction, any provision so invalidated shall be deemed to be separable from the other provisions hereof, and the remaining provisions hereof shall continue to be valid and fully enforceable. 

15.    Relation to Plan. This Agreement is subject to the terms and conditions of the Plan. This Agreement
and the Plan contain the entire agreement and understanding of the parties with respect to the subject matter contained in this Agreement, and supersede all prior written or oral communications, representations and negotiations in respect thereto.
In the event of any inconsistency between the provisions of 

  
 - 3 - 

 
this Agreement and the Plan, the Plan shall govern except with respect to Section 2(a) of this Agreement. Capitalized terms used herein without definition shall have the meanings assigned to
them in the Plan. The Committee acting pursuant to the Plan, as constituted from time to time, shall, except as expressly provided otherwise herein, have the right to determine any questions which arise in connection with the grant of the Option.

 16.    Successors and Assigns. Without limiting Section 5, the provisions of this Agreement shall
inure to the benefit of, and be binding upon, the successors, administrators, heirs, legal representatives and assigns of the Grantee, and the successors and assigns of the Company. 

17.    No Advice Regarding Award. The Company is not providing any tax, legal or financial
advice, nor is the Company making any recommendations regarding the Grantee’s participation in the Plan or the acquisition or sale of the underlying securities. The Grantee is hereby advised to consult with the Grantee’s personal tax,
legal or financial advisors regarding the decision to participate in the Plan before taking any action related to the Plan. 

18.    Governing Law. 

(a)    The interpretation, performance, and enforcement of this Agreement, including tort claims, shall be governed by the
laws of the State of Ohio, without giving effect to the principles of conflict of laws thereof. 
 (b)    Any party
bringing a legal action or proceeding against another party arising out of or relating to this Agreement may bring the legal action or proceeding only in the United States District Court for the Southern District of Ohio and any of the courts of the
State of Ohio, in each case sitting in Cincinnati, Ohio. 
 (c)    Each of the Company and the Grantee waives, to the
fullest extent permitted by law, (i) any objection which it may now or later have to the laying of venue of any legal action or proceeding arising out of or relating to this Agreement brought in any court of the State of Ohio sitting in
Cincinnati, Ohio or the United States District Court for the Southern District of Ohio sitting in Cincinnati, Ohio, including, without limitation, a motion to dismiss on the grounds of forum non conveniens or lack of subject matter
jurisdiction; and (ii) any claim that any action or proceeding brought in any such court has been brought in an inconvenient forum. 

(d)    Each of the Company and the Grantee submits to the exclusive jurisdiction (both personal and subject matter) of
(i) the United States District Court for the Southern District of Ohio sitting in Cincinnati, Ohio and its appellate courts, and (ii) any court of the State of Ohio sitting in Cincinnati, Ohio and its appellate courts, for the purposes of
all legal actions and proceedings arising out of or related to this Agreement. 
 19.    Language. If the
Grantee receives this Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control. 

20.    Electronic Delivery. The Grantee hereby consents and agrees to electronic delivery of any documents
that the Company may elect to deliver (including, but not limited to, prospectuses, prospectus supplements, grant or award notifications and agreements, account statements, annual and quarterly reports, and all other forms of communications) in
connection with this and any other award made or offered under the Plan. The Grantee understands that, unless earlier revoked by the Grantee by giving written notice to the Secretary of the Company, this consent shall be effective for the duration
of the Agreement. The Grantee also understands that he or she shall have the right at any time to request that the Company deliver written copies of any and all materials referred to above at no charge. The Grantee hereby consents to any and all
procedures the Company has established or may establish for an electronic signature system for delivery and acceptance of 

  
 - 4 - 

 
any such documents that the Company may elect to deliver, and agrees that his or her electronic signature is the same as, and shall have the same force and effect as, his or her manual signature.
The Grantee consents and agrees that any such procedures and delivery may be effected by a third party engaged by the Company to provide administrative services related to the Plan. 

IN WITNESS WHEREOF, the Company has caused this Agreement to be executed on its behalf by its duly authorized officer and the Grantee has also
executed this Agreement, as of the Grant Date. 
  

			
	MERIDIAN BIOSCIENCE, INC.
		
	By:	 	                                      
                                         
          
	Name:	 	Bryan T. Baldasare
	Title:	 	Vice President, Corporate Controller and Treasurer

  
 - 5 -EX-10.16.8

 EXHIBIT 10.16.8 

SEVENTH AMENDMENT TO 

LOAN AND SECURITY AGREEMENT 

This Seventh Amendment to Loan and Security Agreement (the “Amendment”) is entered into as of February 6, 2017, by and among
Fifth Third Bank, an Ohio banking corporation (the “Bank”) and Meridian Bioscience, Inc., an Ohio corporation (“Parent” or “Agent”), Meridian Bioscience Corporation, an Ohio corporation
(“Corp.”), Omega Technologies, Inc., an Ohio corporation (“Omega”), Meridian Life Science, Inc., a Maine corporation (“MLS”) and Bioline USA, Inc., a Massachusetts corporation (“Bio”)
(collectively, the “Borrowers” and individually a “Borrower”). 
 WHEREAS, Bank and Borrowers (except Bio) entered into
that certain Loan and Security Agreement, dated as of August 1, 2007, as amended from time to time (the “Agreement”); Bio became a party to the Agreement by an amendment to the Agreement dated December 14, 2012; 

WHEREAS, Bank and Borrowers wish to amend the Agreement to modify certain provisions of the Agreement. 

NOW THEREFORE, intending to be legally bound, the parties hereto agree as follows: 

1.    Section 5.15 of the Agreement is hereby amended and restated in its entirety to read as follows: 

 

	 	 5.15	Fixed Charge Coverage Ratio. At the end of each fiscal quarter, commencing with the fiscal quarter, Borrowers shall maintain a Fixed Charge Coverage Ratio of at least 1.15:1.0. “Fixed Charge Coverage
Ratio” means the ratio of (a) EBITDA for a given measurement period minus the sum of (i) unfunded capital expenditures, (ii) income taxes paid in cash, (iii) distributions and other dividend paid in cash, plus the sum of
(y) all one-time, non-recurring expenses related to the acquisition of Magellan Bioscience, and (z) all non-cash stock
compensation expenses to (b) the sum of (i) interest expense (including the interest portion of any lease which is capitalized under GAAP) payable in cash plus (ii) all principal payments on Funded Indebtedness that were paid by
Borrowers during the measurement period. 

 2.    Representations, Warranties and Covenants of
Borrowers. To induce Bank to enter into this Amendment, Borrowers represent and warrant as follows: 
  

	 	(a)	No Event of Default (as such term is defined in Section 8 of the Agreement) or event or condition which, with the lapse of time or giving of notice or both, would constitute an Event of Default exists on the date
hereof. 

	 	(b)	The person executing this Amendment is a duly elected and acting officer of each Borrower and is duly authorized by the Board of Directors of such Borrower to execute and deliver this Amendment on behalf of such
Borrower. 

 3.    General. 

 

	 	(a)	Except as expressly modified hereby, the Agreement remains unaltered and in full force and effect. Borrowers acknowledge that Bank has made no oral representations to Borrowers with respect to the Agreement and this
Amendment thereto and that all prior understandings between the parties are merged into the Agreement as amended by this writing. All Loans outstanding on the date of execution of this Amendment shall be considered for all purposes to be Loans
outstanding under the Agreement as amended by this Amendment. 

  

	 	(b)	Capitalized terms used and not otherwise defined herein will have the meanings set forth in the Agreement. 

  

	 	(c)	Nothing contained herein will be construed as waiving any default or Event of Default under the Agreement or will affect or impair any right, power or remedy of the Bank under or with respect to the Loans, the
Agreement, or any other agreement or instrument guaranteeing, securing or otherwise relating to the Loans. 

  

	 	(d)	This Amendment shall be considered an integral part of the Agreement, and all references to the Agreement in the Agreement itself or any document referring thereto shall, on and after the date of execution of this
Amendment, be deemed to be references to the Agreement as amended by this Amendment. 

  

	 	(e)	This Amendment will be binding upon and inure to the benefit of Borrowers and Bank and their respective successors and assigns. 

  

	 	(f)	All representations, warranties and covenants made by Borrowers herein will survive the execution and delivery of this Amendment. 

  

	 	(g)	This Amendment will, in all respects, be governed and construed in accordance with the laws of the State of Ohio. 

  

	 	(h)	This Amendment may be executed in one or more counterparts, each of which will be deemed an original and all of which together will constitute one and the same instrument. 

  
 2 

 IN WITNESS WHEREOF, Borrowers and Bank have executed this Agreement by their duly authorized
officers as of the date first above written. 
  

											
	MERIDIAN BIOSCIENCE	 		 	MERIDIAN BIOSCIENCE, INC.
	CORPORATION	 		 		 	
					
	By:	 	 /s/ Melissa A. Lueke
	 		 	By:	 	 /s/ Melissa A. Lueke

		 	Melissa A. Lueke, CFO & Secretary	 		 		 	Melissa A. Lueke, Executive Vice President, CFO & Secretary
			
	OMEGA TECHNOLOGIES, INC.	 		 	MERIDIAN LIFE SCIENCE, INC.
					
	By:	 	 /s/ Melissa A. Lueke
	 		 	By:	 	 /s/ Melissa A. Lueke

		 	Melissa A. Lueke, CFO & Secretary	 		 		 	Melissa A. Lueke, CFO & Secretary
			
	FIFTH THIRD BANK	 		 	BIOLINE USA, INC.
					
	By:	 	 /s/ Drew Hollenkamp
	 		 	By:	 	 /s/ Melissa A. Lueke

		 	Drew Hollenkamp, Vice President	 		 		 		 	Melissa A. Lueke, CFO & Secretary

  
 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00277-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00277-of-00352.parquet"}]]